Produktname:1-(1-ethoxyethyl)-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
IUPAC Name:1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
- CAS：1029716-44-6
- Molekulare Formel：C13H23BN2O3
- Reinheit：95%+
- Katalognummer：CM104626
- Molekulargewicht：266.15
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:1029716-44-6
- Molekulare Formel:C13H23BN2O3
- Schmelzpunkt:-
- SMILES-Code:CCOC(C)N1C=C(C=N1)B1OC(C)(C)C(C)(C)O1
- Dichte:
- Katalognummer:CM104626
- Molekulargewicht:266.15
- Siedepunkt:
- Mdl-Nr.:MFCD11857753
- Lagerung:2-8°C
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
- Boronic Acids and Esters
- Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
- Boronic Acid For Sale
- Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Column Infos
- Povorcitinib
- Incyte announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib, an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN). These data were presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) Annual Meeting.
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for PN.
Suche 
+86 21 5895 0110 
